Clinical Trial Update: Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours [Phase 1]

View source ↗

Summary

Phase 1 study evaluating metabolism, excretion, and pharmacokinetics of a PARP inhibitor in patients with solid metastatic tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• PARP inhibitor (unspecified)

Snippet

Sponsor: AstraZeneca | Conditions: Neoplasm Metastasis | Phase 1 | Status: COMPLETED